Vanguard Group
HUMA icon

Vanguard Group’s Humacyte HUMA Stock Holding History

Vanguard Group’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$8.09M Buy
8,416,971
+896,916
+12% +$1.27M ﹤0.01% 3070
2025
Q3 		$13.1M Buy
7,520,055
+520,431
+7% +$1.02M ﹤0.01% 2829
2025
Q2 		$14.6M Buy
6,999,624
+399,978
+6% +$768K ﹤0.01% 2710
2025
Q1 		$11.3M Buy
6,599,646
+996,962
+18% +$3.74M ﹤0.01% 2779
2024
Q4 		$28.3M Buy
5,602,684
+543,995
+11% +$2.69M ﹤0.01% 2417
2024
Q3 		$27.5M Buy
5,058,689
+329,095
+7% +$2.17M ﹤0.01% 2441
2024
Q2 		$22.7M Buy
4,729,594
+709,913
+18% +$3.69M ﹤0.01% 2508
2024
Q1 		$12.5M Buy
4,019,681
+896,415
+29% +$3.01M ﹤0.01% 2840
2023
Q4 		$8.87M Buy
3,123,266
+104,299
+3% +$268K ﹤0.01% 3016
2023
Q3 		$8.85M Buy
3,018,967
+50,331
+2% +$167K ﹤0.01% 2950
2023
Q2 		$8.49M Buy
2,968,636
+2,359
+0.1% +$8.5K ﹤0.01% 3040
2023
Q1 		$9.17M Buy
2,966,277
+121,014
+4% +$344K ﹤0.01% 2983
2022
Q4 		$6M Buy
2,845,263
+174,140
+7% +$529K ﹤0.01% 3216
2022
Q3 		$8.71M Sell
2,671,123
-2,882
-0.1% -$11.1K ﹤0.01% 3015
2022
Q2 		$8.58M Buy
2,674,005
+251,985
+10% +$1.4M ﹤0.01% 3075
2022
Q1 		$17.1M Buy
2,422,020
+1,253,788
+107% +$7.3M ﹤0.01% 2859
2021
Q4 		$8.47M Buy
1,168,232
+878,123
+303% +$8.69M ﹤0.01% 3311
2021
Q3 		$3.37M Buy
+290,109
New +$3.32M ﹤0.01% 3869

Other funds holding HUMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Vanguard Group's HUMA Position: Q4 2025 in Review

Vanguard Group increased its Humacyte (HUMA) stake by 12% in Q4 2025, buying an estimated $1.27M and bringing the position to 8,416,971 shares worth $8.09M. The position accounts for ﹤0.01% of the portfolio, ranked #3070.

Vanguard Group first reported a position in HUMA in Q3 2021 and has held it in 18 quarters since. The position peaked at $28.3M in Q4 2024. 147 funds tracked by Wall St. Rank hold HUMA as of Q4 2025.

  • Vanguard Group held 8,416,971 shares of Humacyte worth $8.09M as of Q4 2025.
  • Vanguard Group bought 896,916 Humacyte shares in Q4 2025, an estimated $1.27M.
  • Humacyte made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3070 holding.
  • Vanguard Group first reported a position in Humacyte in Q3 2021 and has held it in 18 quarters since.
  • Vanguard Group's Humacyte position peaked at $28.3M in Q4 2024.
  • 147 funds tracked by Wall St. Rank held Humacyte as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.